Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTM201 in post-stroke upper limb spasticity
NCT07292025Phase 1Completed
- Sponsor
- JETEMA Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in Upper limb spasticity (2 arms), sponsored by JETEMA Co., Ltd. Primary endpoints: Modified Ashworth Scale Wrist Flexor at 12 weeks, Modified Ashworth Scale Elbow Flexor and Finger Flexor at 12 weeks and 5 more. Started Jun 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT07292025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292025.